哈佛生物学教授因冠状病毒而成为亿万富翁

哈佛生物学教授、蒂莫西·斯普林格（Timothy Springer）在10年前一家押注并投资约500万美元给一家名为摩德纳公司（Moderna）的生物科技公司；该公司目前正在进行Covid-19疫苗的人体临床试验。本周随着摩德纳公司的股票上涨超过12%，现在这笔初始投资价值近8.7亿美元。他一跃成了亿万富翁。《福布斯》估计，根据他在摩德纳3.5%的股权再加上其它三家规模较小的生物技术公司的股权，他目前的身家为10亿美元。其实自3月11日世界卫生组织宣布全球疫情大流行以来，一些医疗亿万富翁的财富已经增加了数十亿美元。并且随着公众热切期待着Covid-19疫苗的新进展，生物技术行业会更加快速的发展。

Hharvard biology professor and serial entrepreneur Timothy Springer saw promise in a fledgling biotech firm a decade ago and he put about $5 million into the company as an early investment.  Now, a decade later, that initial investment is worth nearly $870 million. Now, primarily as a result of that bet — on a Cambridge, Massachusetts company called Moderna — he’s a billionaire. Shares of Moderna, which has a Covid-19 vaccine currently in human clinical trials, rose more than 12% this week, bucking the overall drop in the stock market. That surge has turned Springer into a billionaire: Forbes estimates he is now worth $1 billion based on his 3.5% equity stake in Moderna and stakes in three smaller biotech outfits. Some healthcare billionaires’ fortunes have risen by billions of dollars since the WHO declared a global pandemic on March 11. The biotech rally could keep gathering pace as the public eagerly awaits new developments in the fight against Covid-19.  source

指尖新闻：高信噪比，一目了然

新冠疫情追踪